地舒单抗治疗骨转移疗效如何呢？

How effective is the treatment of bone metastasis? Desomasumab was approved for marketing in my country in 2019. Desomasumab injection is currently the only drug used for the treatment of giant cell tumor of bone. Its therapeutic effect has always been a matter of great concern to everyone. The following medical companions have compiled some relevant information in the hope that it can bring you some help.

In one trial, denosumab was better than zoledronic acid in preventing complications of bone metastases from solid tumors or multiple myeloma. Compared with zoledronic acid, denosumab can significantly delay the occurrence of SREs in patients with breast cancer bone metastases and reduce the risk of multiple SREs by 23%.

Desosumab for the treatment of giant cell tumor of bone is based on the results of two open-label trials in patients with recurrent, unresectable giant cell tumor of bone or in whom planned surgical resection is likely to cause severe functional disability.

The latest analysis of the study, presented at the European Society for Medical Oncology (ESMO) Annual Meeting in 2017, showed that among patients who could be surgically resected, 80% improved with neoadjuvant denosumab: 44% underwent surgery with less functional impact and 37% avoided surgery. In unresectable patients, denosumab resulted in effective long-term disease control with a 5-year progression-free survival (PFS) rate of 88%.

Peixi Wen, vice president and general manager of Amgen's Asia Pacific region, said: "As the first and currently the only drug for the treatment of giant cell tumor of bone approved in China, the injection is of extraordinary significance to patients suffering from this rare disease, especially those who are unable to undergo surgery or whose surgery will cause severe disabilities. We are excited about this." At the same time, denosumab injection (Angavir®) is the first cancer treatment drug brought by Amgen to Chinese patients. It will inject new impetus into our development in the Chinese market and lay the foundation for the development of the oncology field.